Sirtex.com website

Sponsor and SIR-Spheres Y-90 resin microspheres

Sirtex Medical Limited

The FOXFIRE Global study is sponsored by Sirtex Technology Pty Ltd., a wholly owned subsidiary of Sirtex Medical Limited (Sirtex). Headquartered in Sydney, Australia, Sirtex is a public company listed on the Australian Securities Exchange (ASX: SRX). The primary objective of Sirtex is to research, develop, and commercialise effective treatments for liver cancer using novel small particle technology.

About SIR-Spheres Y-90 resin microspheres

About SIR-Spheres microspheres

SIR-Spheres Y-90 resin microspheres are biocompatible polymer microspheres containing yttrium-90 with a size between 20 and 60 microns in diameter. A high-energy beta-emitting isotope, Yttrium-90 has a half-life of 64.1 hours. The maximum range of emissions in tissue is 11mm with a mean of 2.5mm. In therapeutic use, requiring the isotope to decay to infinity, 94% of the radiation is delivered in 11 days. SIR-Spheres Y-90 resin microspheres distribute non-uniformly in the liver due to the physiology of hepatic arterial flow, the tumour to normal liver ratio of the tissue vascularity and tumour size. The rim of the tumour gets higher density per unit distribution of SIR-Spheres Y-90 resin microspheres than the normal liver. SIR-Spheres Y-90 resin microspheres are a sealed-source device.

SIR-Spheres Y-90 resin microspheres package insert are available for download and print:

 

 

W007-EUA-0315